EOLS News and Press, Evolus Inc. From 01/26/24

2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group  ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus,  ( EOLS ) +2% . SSR Mining  ( SSRM ) +2% . Losers: Progress Software ...

Evolus, Inc. (NASDAQ: EOLS) is one of today's top gainers. The company's shares have moved -1.56% on the day to $7.59. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 ki...

2024-01-17 10:00:18 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Health stocks to watch this earnings season as sector poised for resurgence Seeking Al...

2024-01-16 17:58:56 ET More on Evolus Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript Public Citizen petitions FDA for stricter warnings against Botox, similar drugs Evolus GAAP EPS of ...

Preliminary Unaudited Net Revenue of Approximately $61 Million for the Fourth Quarter 2023, Representing 40% Growth Over the Prior Year Quarter and a 22% Increase Over the Prior Sequential Quarter Preliminary Unaudited Net Revenue of Approximately $202 Million for the Full-Year 2023, ...

2024-01-10 16:46:06 ET More on AbbVie AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen Investor's Dilemma: AbbVie Stock Amidst U.S. Election And Humira Decline AbbVie announces EU availa...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be ...

Exclusive Distributor Agreement with Symatese Broadens Evolus’ Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and Europe European Regulatory Approvals Anticipated in Second Half of 2024 Company Continues to Expect to be Fully Funded to Profitability ...

2023-12-15 10:13:35 ET Summary Evolus stock failed to push higher after a bullish rating due to a prolonged consolidation period. Technical analysis suggests potential for a bullish breakout, but there are risks and uncertainties. Evolus' future growth and valuation are heavil...

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...